All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
non squamous - mNSCLC - L1 - all population, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02]
0.80 [0.72 ; 0.90 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 3 0% 2,325 moderate not evaluable progression or deaths (PFS)detailed results IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06]
0.71 [0.55 ; 0.92 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 3 86% 2,325 moderate not evaluable objective responses (ORR)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35]
1.41 [0.75 ; 2.66 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 2 90% 1,594 moderate not evaluable AE (any grade)detailed results IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65]
0.81 [0.21 ; 3.04 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 32% 1,492 moderate not evaluable AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52]
1.38 [0.93 ; 2.05 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 67% 1,492 moderate not evaluable AE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03]
1.03 [0.65 ; 1.62 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99]
1.38 [1.09 ; 1.75 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable SAE (any grade)detailed results IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87]
1.52 [1.23 ; 1.89 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable STRAE (any grade)detailed results IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00]
1.68 [1.16 ; 2.43 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 45% 1,492 moderate not evaluable TRAE (any grade)detailed results IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53]
1.26 [0.52 ; 3.06 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 72% 1,492 moderate not evaluable TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83]
1.55 [1.20 ; 1.99 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 28% 1,492 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
1.49 [0.64 ; 3.48 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 2% 1,492 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09]
1.00 [0.06 ; 16.09 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
0.70 [0.04 ; 11.23 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89]
1.39 [0.92 ; 2.09 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 33% 1,492 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37]
0.75 [0.17 ; 3.37 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30]
0.76 [0.24 ; 2.44 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 48% 1,492 moderate not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10]
2.53 [0.49 ; 13.10 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
0.99 [0.08 ; 12.92 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
1.41 [0.34 ; 5.85 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 31% 1,492 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
1.00 [0.02 ; 50.65 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63]
2.11 [0.40 ; 10.96 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 75% 1,492 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03]
1.12 [0.67 ; 1.88 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57]
1.48 [0.85 ; 2.57 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hypertension TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78]
1.00 [0.57 ; 1.78 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Increase AST TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09]
1.77 [0.51 ; 6.09 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26]
2.01 [0.18 ; 22.26 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57]
1.80 [0.90 ; 3.58 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94]
1.24 [0.95 ; 1.62 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56]
4.03 [0.18 ; 89.56 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97]
0.50 [0.02 ; 14.97 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
1.23 [0.50 ; 3.01 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15]
3.04 [0.61 ; 15.15 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27]
10.14 [0.55 ; 186.27 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Sepsis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89]
1.24 [0.78 ; 1.97 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 3% 1,492 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99]
1.32 [0.55 ; 3.21 ] IMpower-130 (all population), 2019, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,492 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.23 [0.24; 6.38]
1.23 [0.24 ; 6.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.47 [1.03; 2.11]
1.47 [1.03 ; 2.11 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 7.97 [0.46; 139.30]
7.97 [0.46 ; 139.30 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
1.59 [0.58 ; 4.39 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Back pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
3.97 [0.49 ; 31.97 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-130 (all population), 2019 4.95 [0.27; 90.93]
4.95 [0.27 ; 90.93 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Cough AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.33; 2.90]
0.98 [0.33 ; 2.90 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.87 [0.44; 1.70]
0.87 [0.44 ; 1.70 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 5.61 [1.31; 24.06]
5.61 [1.31 ; 24.06 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.28 [0.68; 2.43]
1.28 [0.68 ; 2.43 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.90 [0.33; 2.46]
0.90 [0.33 ; 2.46 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Gastritis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Headache AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.30; 7.38]
1.48 [0.30 ; 7.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.20; 2.62]
0.73 [0.20 ; 2.62 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.57 [0.66; 3.73]
1.57 [0.66 ; 3.73 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Myalgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
1.59 [0.58 ; 4.39 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.24 [0.88; 1.75]
1.24 [0.88 ; 1.75 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.07; 3.49]
0.49 [0.07 ; 3.49 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.40 [0.67; 2.93]
1.40 [0.67 ; 2.93 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Rash AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.09; 10.87]
0.98 [0.09 ; 10.87 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Sepsis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 6.95 [0.39; 123.09]
6.95 [0.39 ; 123.09 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.02; 2.70]
0.24 [0.02 ; 2.70 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.49 [0.83; 2.69]
1.49 [0.83 ; 2.69 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.28 [0.45; 3.64]
1.28 [0.45 ; 3.64 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.09; 10.87]
0.98 [0.09 ; 10.87 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-15 08:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 165
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
